1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Market Spotlight: Hodgkin’s Lymphoma, Pharma Intelligence

Market Spotlight: Hodgkin’s Lymphoma, Pharma Intelligence

  • October 2019
  • 42 pages
  • ID: 5780051
  • Format: PDF
  • By Pharma Intelligence


Table of Contents

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways
The analyst estimates that in 2017, there were 78,600 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 86,000 incident cases by 2026.
In the same year, there were approximately 272,100 five-year prevalent cases of Hodgkin’s lymphoma worldwide, which is expected to increase to 297,700 cases by 2026.
The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.
The majority of the industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II, with no drugs in Phase III.
Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the oral or intravenous routes, with only one product being tested in an intratumoral formulation.
High-impact upcoming events for drugs in the Hodgkin’s lymphoma space comprise topline Phase II trial results for AFM13 and ADCT-301, and topline Phase III trial results and an estimated PDUFA date for Keytruda.
The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.3%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been 41 licensing and asset acquisition deals involving Hodgkin’s lymphoma drugs during 2014–19. The largest deal was the $1,456m collaboration agreement in 2015 between Eli Lilly and Innovent Biologics for the development and potential commercialization of at least three cancer treatments over the next decade.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 49 trials.
Takeda leads industry sponsors with by far the highest number of clinical trials for Hodgkin’s lymphoma, followed by Merck and Co.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Histone Deacetylase 6 - Pipeline Review, H2 2019

Histone Deacetylase 6 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Histone Deacetylase 6 - Pipeline Review, H2 2019SummaryHistone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC pipeline Target constitutes close to 49 molecules. Out ...

Histone Deacetylase 3 - Pipeline Review, H2 2019

Histone Deacetylase 3 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Histone Deacetylase 3 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Histone Deacetylase 3 - Pipeline Review, H2 2019’; Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 ...

Tyrosine Protein Kinase SYK - Pipeline Review, H1 2020

Tyrosine Protein Kinase SYK - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Tyrosine Protein Kinase SYK - Pipeline Review, H1 2020SummaryTyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC - Spleen tyrosine kinase, also known as Syk, is an enzyme ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on